Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Coronary Occlusion | 2 | 2021 | 12 | 1.530 |
Why?
|
| Case-Control Studies | 5 | 2022 | 1553 | 0.850 |
Why?
|
| Neurosurgical Procedures | 1 | 2022 | 98 | 0.750 |
Why?
|
| Neurosurgeons | 2 | 2019 | 22 | 0.700 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2021 | 134 | 0.680 |
Why?
|
| Atherosclerosis | 1 | 2021 | 204 | 0.660 |
Why?
|
| Research Report | 1 | 2019 | 35 | 0.650 |
Why?
|
| Neurosurgery | 1 | 2019 | 42 | 0.640 |
Why?
|
| Triage | 1 | 2019 | 109 | 0.620 |
Why?
|
| Intracranial Aneurysm | 4 | 2020 | 87 | 0.600 |
Why?
|
| Intensive Care Units | 1 | 2019 | 344 | 0.570 |
Why?
|
| Research Design | 2 | 2019 | 729 | 0.520 |
Why?
|
| Reoviridae | 1 | 2014 | 14 | 0.470 |
Why?
|
| Oncolytic Virotherapy | 1 | 2014 | 15 | 0.460 |
Why?
|
| Glioma | 1 | 2014 | 140 | 0.420 |
Why?
|
| Precipitating Factors | 2 | 2021 | 3 | 0.390 |
Why?
|
| Anger | 2 | 2021 | 47 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 446 | 0.380 |
Why?
|
| Endovascular Procedures | 3 | 2019 | 366 | 0.370 |
Why?
|
| Stroke | 2 | 2022 | 2163 | 0.360 |
Why?
|
| Intracranial Arteriovenous Malformations | 2 | 2020 | 15 | 0.310 |
Why?
|
| Embolization, Therapeutic | 2 | 2019 | 150 | 0.290 |
Why?
|
| Carotid Artery Injuries | 2 | 2018 | 26 | 0.290 |
Why?
|
| Humans | 23 | 2022 | 68618 | 0.290 |
Why?
|
| Brain Ischemia | 2 | 2022 | 665 | 0.250 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2016 | 131 | 0.240 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 236 | 0.180 |
Why?
|
| Thrombectomy | 2 | 2022 | 238 | 0.180 |
Why?
|
| Arteriovenous Fistula | 1 | 2020 | 25 | 0.180 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2019 | 3 | 0.180 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2019 | 5 | 0.170 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2020 | 127 | 0.170 |
Why?
|
| Carotid Artery, Internal | 1 | 2019 | 85 | 0.170 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 80 | 0.170 |
Why?
|
| Cerebral Hemorrhage | 2 | 2020 | 198 | 0.160 |
Why?
|
| Cigarette Smoking | 1 | 2020 | 104 | 0.160 |
Why?
|
| Aspirin | 1 | 2020 | 295 | 0.160 |
Why?
|
| Marfan Syndrome | 1 | 2018 | 42 | 0.160 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2018 | 61 | 0.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 212 | 0.150 |
Why?
|
| Publishing | 1 | 2019 | 89 | 0.150 |
Why?
|
| Middle Aged | 11 | 2020 | 21147 | 0.140 |
Why?
|
| Cerebrovascular Trauma | 1 | 2016 | 7 | 0.140 |
Why?
|
| Aged | 9 | 2022 | 14862 | 0.140 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2016 | 34 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2018 | 294 | 0.130 |
Why?
|
| Injury Severity Score | 1 | 2016 | 204 | 0.130 |
Why?
|
| Computed Tomography Angiography | 2 | 2018 | 424 | 0.130 |
Why?
|
| Benzaldehydes | 1 | 2015 | 8 | 0.130 |
Why?
|
| Female | 13 | 2022 | 38074 | 0.130 |
Why?
|
| Radiosurgery | 1 | 2016 | 66 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 57 | 0.130 |
Why?
|
| Spinal Injuries | 1 | 2015 | 30 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 110 | 0.120 |
Why?
|
| Oncolytic Viruses | 1 | 2014 | 17 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 206 | 0.120 |
Why?
|
| Seizures | 1 | 2016 | 279 | 0.110 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2015 | 105 | 0.110 |
Why?
|
| Adult | 8 | 2020 | 21403 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2022 | 7277 | 0.100 |
Why?
|
| Hypertension | 1 | 2020 | 1535 | 0.090 |
Why?
|
| Male | 9 | 2022 | 37321 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2022 | 3705 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2019 | 2358 | 0.080 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2020 | 181 | 0.080 |
Why?
|
| Angiography, Digital Subtraction | 2 | 2019 | 63 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2022 | 7029 | 0.070 |
Why?
|
| Cerebral Angiography | 2 | 2019 | 151 | 0.070 |
Why?
|
| Anticonvulsants | 2 | 2018 | 223 | 0.060 |
Why?
|
| Observer Variation | 2 | 2016 | 330 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2005 | 219 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 468 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 39 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 371 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3259 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2077 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 267 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 68 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2018 | 32 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2018 | 65 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 1070 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 306 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 373 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 1426 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2019 | 310 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 132 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2015 | 137 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 115 | 0.030 |
Why?
|
| Young Adult | 2 | 2016 | 5717 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 1465 | 0.030 |
Why?
|
| Aneurysm, False | 1 | 2015 | 60 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 381 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2279 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2018 | 866 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 2223 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 5731 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1851 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1851 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7367 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 4848 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2005 | 26 | 0.020 |
Why?
|
| Hydroxyurea | 1 | 2005 | 57 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2324 | 0.020 |
Why?
|
| Child | 1 | 2016 | 6405 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2005 | 411 | 0.020 |
Why?
|
| Benzamides | 1 | 2005 | 156 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2005 | 178 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 567 | 0.010 |
Why?
|
| Piperazines | 1 | 2005 | 206 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 714 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 8912 | 0.010 |
Why?
|
| Disease Progression | 1 | 2005 | 1038 | 0.010 |
Why?
|